Current management of erectile dysfunction after cancer treatment

Current Opinion in Oncology

Volumn 21, Issue 4, 2009, Pages 303-309

  Peltier, Alexandre ^a   Van Velthoven, Roland ^a   Roumeguère, Thierry ^b  

^a JULES BORDET INSTITUTE   (Belgium)

^b ERASME HOSPITAL   (Belgium)

Author keywords

Patient and partner counseling; Penile rehabilitation; Phosphodiesterase type 5 inhibitors; Postcancer treatment erectile dysfunction

Indexed keywords

PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROSTAGLANDIN E1; SILDENAFIL; TADALAFIL; VARDENAFIL; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE V;

BRACHYTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL TRIAL; COUNSELING; ERECTILE DYSFUNCTION; EVENING DOSAGE; EXTERNAL BEAM RADIOTHERAPY; HORMONAL THERAPY; HUMAN; LOW DRUG DOSE; NONHUMAN; OXYGENATION; PRIORITY JOURNAL; PROSTATE CANCER; PSYCHOLOGICAL ASPECT; REVIEW; VACUUM; DRUG ANTAGONISM; MALE; PROSTATE TUMOR; PROSTATECTOMY; RADIOTHERAPY;

ALPROSTADIL; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; ERECTILE DYSFUNCTION; HUMANS; MALE; PHOSPHODIESTERASE INHIBITORS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY;

EID: 67650306408     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32832b9d76     Document Type: Review

References (42)

1. Miles CL, Candy B, Jones L, et al. Interventions for sexual dysfunction following treatments for cancer. Cochrane Database Syst Rev 2007: CD005540. doi: 10. 1002/14651858. CD005540. pub2.
2. Wespes E, Amar E, Hatzichristou D, et al. EAU Guidelines on erectile dysfunction: an update. Eur Urol 2006; 49:806-815.
3. Mulhall JP, Simmons J. Assessment of comparative treatment satisfaction with sildenafil citrate and penile injection therapy in patients responding to both. BJU Int 2007; 100:1313-1316.
4. Manne S, Badr H. Intimacy and relationship processes in couples' psychosocial adaptation to cancer. Cancer 2008; 112 (11 Suppl):2541-2555.
5. Moriya Y. Function preservation in rectal cancer surgery. Int J Clin Oncol 2006; 11:339-343.
6. Wittmann D, Northouse L, Foley S, et al. The psychosocial aspects of sexual recovery after prostate cancer treatment. Int J Impot Res 2009; 21:99-106. doi:10. 1038/ijir. 2008. 66.
7. Glina S. How much are patients interested in erectile dysfunction treatment after radical prostatectomy? Eur Urol 2008; 53:461 -462; discussion 462-464.
8. Pinkawa M, Gagel B, Piroth MD, et al. Erectile dysfunction after external beam radiotherapy for prostate cancer. Eur Urol 2008; 55:227-236.
9. Akbal C, Tinay I, Simsek F, Turkeri LN. Erectile dysfunction following radiotherapy and brachytherapy for prostate cancer: pathophysiology, prevention and treatment. Int Urol Nephrol 2008; 40:355-363.
10. Walz J, Perrotte P, Suardi N, et al. Baseline prevalence of erectile dysfunction in a prostate cancer screening population. J Sex Med 2008; 5:428-435.
11. Rosen RC, RileyA, WagnerG, et al. Theinternational indexoferectilefunction (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49:822-830.
12. Quinlan DM, Epstein JI, Carter BS, Walsh PC. Sexual function following radical prostatectomy: influence of preservation of neurovascular bundles. J Urol 1991; 145:998-1002.
13. Secin FP, Touijer K, Mulhall J, Guillonneau B. Anatomy and preservation of accessory pudendal arteries in laparoscopic radical prostatectomy. Eur Urol 2007; 51:1229-1235.
14. Mulhall JP. Penile rehabilitation following radical prostatectomy. Curr Opin Urol 2008; 18:613-620.
15. User HM, Hairston JH, Zelner DJ, et al. Penile weight and cell subtype specific changes in a postradical prostatectomy model of erectile dysfunction. J Urol 2003; 169:1175-1179.
16. Ruiz Rubio JL, Hernandez M, Rivera de los Arcos L, et al. Mechanisms of prostaglandin E1-induced relaxation in penile resistance arteries. J Urol 2004; 171 (2 Pt 1):968-973.
17. Kovanecz I, Rambhatla A, Ferrini MG, et al. Chronic daily tadalafil prevents the corporal fibrosis and veno-occlusive dysfunction that occurs after cavernosal nerve resection. BJU Int 2007; 101:203-210.
18. Schwartz EJ, Wong P, Graydon RJ. Sildenafil preserves intracorporeal smooth muscle after radical retropubic prostatectomy. J Urol 2004; 171 (2 Pt 1):771 -774.
19. LysiakJJ, Yang SK, Klausner AP, et al. Tadalafil increases Akt and extracellular signal-regulated kinase1/2 activation, andpreventsapoptoticcell death in the penis following denervation. J Urol 2008; 179:779-785.
20. Ferrini MG, Davila HH, Kovanecz I, et al. Vardenafil prevents fibrosis and loss of corporal smooth muscle that occurs after bilateral cavernosal nerve resection in the rat. Urology 2006; 68:429-435.
21. Ferrini MG, KovaneczI, SanchezS, et al. Long-term continuoustreatmentwith sildenafil ameliorates aging-related erectile dysfunction and the underlying corporal fibrosis in the rat. Biol Reprod 2007; 76:915-923.
22. Montorsi F, Luigi GG, Strambi LF, et al. Recovery of spontaneous erectile function after nerve-sparing radical retropubic prostatectomywith and without early intracavernous injections of alprostadil: results of a prospective, randomized trial. J Urol 1997; 158:1408-1410.
23. Padma-Nathan H, McCullough AR, Levine LA, et al. Randomized, double- blind, placebo-controlled study of postoperative nightly sildenafil citrate for the prevention of erectile dysfunction after bilateral nerve-sparing radical prostatectomy. Int J Impot Res 2008; 20:479-486.
24. Mulhall J, Land S, Parker M, et al. The use ofan erectogenic pharmacotherapy regimen following radical prostatectomy improves recovery of spontaneous erectile function. J Sex Med 2005; 2:532-540.
25. BannowskyA, Schulze H, van derHorstC, et al. Recoveryoferectile function after nerve-sparing radical prostatectomy: improvement with nightly low dose sildenafil. BJU Int 2008; 101:1279-1283.
26. Gontero P, Fontana F, Bagnasacco A, et al. Is there an optimal time for intracavernous prostaglandin E1 rehabilitation following non nerve sparing radical prostatectomy? Resultsfrom ahemodynamic prospective study. J Urol 2003; 169:2166-2169.
27. Raina R, Pahlajani G, Agarwal A, Zippe CD. The early use of transurethral alprostadil afterradical prostatectomypotentiallyfacilitatesan earlierreturn of erectile function and successful sexual activity. BJU Int 2007; 100:1317-1321.
28. Gallina A, Salonia A, Briganti A, et al. Prevention and management of post prostatectomy erectile dysfunction. Eur Urol 2009; 8:80-87.
29. McCullough AR, Levine LA, Padma-Nathan H. Return ofnocturnal erections and erectile function after bilateral nerve-sparing radical prostatectomy in men treated nightly with sildenafil citrate: subanalysis of a longitudinal randomized double-blind placebo-controlled trial. J Sex Med 2008; 5:476-484.
30. Montorsi F, BrockG, Lee J, et al. Effect of nightly versus on-demand vardenafil on recovery of erectile function in men following bilateral nerve-sparing radical prostatectomy. Eur Urol 2008; 54:924-931.
31. Penson DF, McLerran D, Feng Z, et al. 5-year urinary and sexual outcomes after radical prostatectomy: results from the Prostate Cancer Outcomes Study. J Urol 2008; 179 (5 Suppl):S40-S44.
32. Salonia A, Gallina A, Zanni G, et al. Acceptance of and discontinuation rate from erectile dysfunction oral treatment in patients following bilateral nerve- sparing radical prostatectomy. Eur Urol 2008; 53:564-570.
33. van der Wielen GJ, Mulhall JP, Incrocci L. Erectile dysfunction after radiotherapy for prostate cancer and radiation dose to the penile structures: a critical review. Radiother Oncol 2007; 84:107-113.
34. Incrocci L, Koper PC, Hop WC, Slob AK. Sildenafil citrate (Viagra) and erectile dysfunction following external beam radiotherapy for prostate cancer: a randomized, double-blind, placebo-controlled, cross-over study. Int J Radiat Oncol Biol Phys 2001; 51:1190-1195.
35. Incrocci L, Slagter C, Slob AK, Hop WC. A randomized, double-blind, placebo-controlled, cross-over study to assess the efficacy of tadalafil (Cialis) in the treatment oferectile dysfunction following three-dimensional conformal external-beam radiotherapy for prostatic carcinoma. Int J Radiat Oncol Biol Phys 2006; 66:439-444.
36. Incrocci L, Slob AK, Hop WC. Tadalafil (Cialis) and erectile dysfunction after radiotherapy for prostate cancer: an open-label extension of a blinded trial. Urology 2007; 70:1190-1193.
37. Lee IH, Sadetsky N, Carroll PR, Sandler HM. The impact of treatment choice for localized prostate cancer on response to phosphodiesterase inhibitors. J Urol 2008; 179:1072-1076; discussion 1076.
38. DiBlasio CJ, Malcolm JB, Derweesh IH, et al. Patterns of sexual and erectile dysfunction and response to treatment in patients receiving androgen deprivation therapy for prostate cancer. BJU Int 2008; 102:39-43.
39. Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008; 358:1250-1261.
40. Badr H, Carmack Taylor CL. Sexual dysfunction and spousal communication in couples coping with prostate cancer. Psychooncology 2008 [Epub ahead of print]. doi:10. 1002/pon. 1449.
41. Northouse LL, Mood DW, Schafenacker A, et al. Randomized clinical trial ofa family intervention for prostate cancer patients and their spouses. Cancer 2007; 110:2809-2818.
42. Albersen M, Joniau S, Claes H, Van Poppel H. Preclinical evidence for the benefits of penile rehabilitation therapy following nerve-sparing radical prostatectomy. Advances Urol 2008. doi:10. 1155/2008/594868.